OraSure’s Quick HCV Test: Many Settings, One Goal
This article was originally published in The Pink Sheet Daily
Executive Summary
Flexible diagnostic, like HIV test, could identify more patients faster.
You may also be interested in...
Vertex Kicks Off Telaprevir Pivotal Trial Next Month
Abbreviated 24-week HCV therapy regimen with telaprevir could also prove itself in vast population of treatment non-responders, company says.
Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.